Safety of palliative chemotherapy in advanced pancreatic cancer

References

• Hidalgo M. Pancreatic cancer. The New England Journal of Medicine. 2010 May 29;362(17):1605–1617. PubMed PMID: 20427809.
   PubMed Web of Science ®Google Scholar
• Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011 Aug 13;378(9791):607–620. PubMed PMID: 21620466.
   Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1;74(11):2913–2921. PubMed PMID: 24840647.
   PubMed Web of Science ®Google Scholar
• Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013 Jul;6(4):321–337. PubMed PMID: 23814611.
   PubMed Web of Science ®Google Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clinic Oncol. 1997;15(6):2403–2413. PubMed PMID: 9196156.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2007 Jun 20;25(15):1960–1966. PubMed PMID: 17452677. eng.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 Jun 12;364(19):1817–1825. PubMed PMID: 21561347.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 Oct 31;369(18):1691–1703. PubMed PMID: 24131140.
   PubMed Web of Science ®Google Scholar
• Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014 Feb;79:34–74. PubMed PMID: 24269963.
   PubMed Web of Science ®Google Scholar
• Steffens M, Paul T, Hichert V, et al. Dosing to rash? - The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash. Eur J Cancer. 2016 Mar;55:131–139. PubMed PMID: 26820683.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Li CP, Nowara E, et al. Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study. Br J Cancer 2014 Nov 25;111(11):2067–2075. PubMed PMID: 25247318; Pubmed Central PMCID: 4260026.
   PubMed Web of Science ®Google Scholar
• Danson S, Blackhall F, Hulse P, et al. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 2005;28(2):103–113. PubMed PMID: 15691221.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548–4554. PubMed PMID: 21969517.
   PubMed Web of Science ®Google Scholar
• Goldstein D, Von Hoff DD, Moore M, et al. Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). Eur J Cancer. 2016 Jan;52:85–91. PubMed PMID: 26655559.
   PubMed Web of Science ®Google Scholar
• Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423–2429. PubMed PMID: 24982456.
   PubMed Web of Science ®Google Scholar
• Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016 Feb 6;387(10018):545–557. PubMed PMID: 26615328.
   PubMed Web of Science ®Google Scholar
• Gresham GK, Wells GA, Gill S, et al., Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis. BMC Cancer. 2014;14:471. PubMed PMID: 24972449; Pubmed Central PMCID: 4097092.
   PubMed Web of Science ®Google Scholar
• Ghorani E, Wong HH, Hewitt C, et al. Safety and efficacy of modified FOLFIRINOX for advanced pancreatic adenocarcinoma: a UK single-centre experience. Oncology. 2015;89(5):281–287. PubMed PMID: 26372905.
   PubMed Web of Science ®Google Scholar
• Terazawa T, Goto M, Miyamoto T, et al. Efficacy of prophylactic G-CSF in patients receiving FOLFIRINOX: a preliminary retrospective study. Internal Medicine. 2015;54(23):2969–2973. PubMed PMID: 26631878.
   PubMed Web of Science ®Google Scholar
• Umemura A, Nitta H, Sasaki A, et al. Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience. Hepato-gastroenterology. 2014 May;61(131):814–820. PubMed PMID: 26176079.
   PubMed Web of Science ®Google Scholar
• Oikonomopoulos GM, Syrigos KN, Skoura E, et al. FOLFIRINOX: from the ACCORD study to 2014. JOP. 2014 Mar;15(2):103–105. PubMed PMID: 24618428.
   PubMedGoogle Scholar
• Peixoto RD, Ho M, Renouf DJ, et al. Eligibility of metastatic pancreatic cancer patients for first-line palliative intent nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Am J Clin Oncol. 2015 Apr 1. PubMed PMID: 25844823. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Marsh RDW, Talamonti MS, Katz MH, et al. Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer Med. 2015 Jun;4(6):853–863. PubMed PMID: 25693729.
   Web of Science ®Google Scholar
• Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012;13(5):497–501. PubMed PMID: 22964956.
   PubMedGoogle Scholar
• Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015 Jun;12(6):319–334. PubMed PMID: 25824606.
   PubMed Web of Science ®Google Scholar
• Conroy T, Bachet JB, Ayav A, et al. Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer. 2016 Feb 3;57:10–22. PubMed PMID: 26851397.
   PubMed Web of Science ®Google Scholar
• Vogel A, Kullmann F, Kunzmann V, et al. Patients with advanced pancreatic cancer and hyperbilirubinaemia: review and german expert opinion on treatment with nab-paclitaxel plus gemcitabine. Oncol Res Treat. 2015;38(11):596–603. PubMed PMID: 26599274.
   PubMed Web of Science ®Google Scholar
• Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology (Williston Park). 2005 Jul;19(8):1057–1063. discussion 63-4, 69. PubMed PMID: 16131047.
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007 Sep 15;110(6):1376–1384. PubMed PMID: 17634949.
   PubMed Web of Science ®Google Scholar
• Stingl JC, Bartels H, Viviani R, et al. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol Ther. 2014 Jan;141(1):92–116. PubMed PMID: 24076267.
   PubMed Web of Science ®Google Scholar
• Di Paolo A, Bocci G, Polillo M, et al. Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity. Curr Drug Metab. 2011;12(10):932–943. PubMed PMID: 21787264.
   PubMed Web of Science ®Google Scholar
• Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics. 2010 Jul;11(7):1003–1010. PubMed PMID: 20602618; Pubmed Central PMCID: 2927346.
   PubMed Web of Science ®Google Scholar
• Lunenburg CA, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer. 2016 Feb;54:40–48. PubMed PMID: 26716401.
   PubMed Web of Science ®Google Scholar
• Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23(Suppl 7):vii33–vii40. PubMed PMID: 22997452.
   PubMedGoogle Scholar
• Kristensen A, Vagnildhaug OM, Gronberg BH, et al. Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? a systematic review. Crit Rev Oncol Hematol. 2016 Mar;99:286–298. PubMed PMID: 26819138.
   PubMed Web of Science ®Google Scholar
• Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013 Jan 1 1;31:23–29. PubMed PMID: 23213101.
   PubMed Web of Science ®Google Scholar
• Jang RW, Krzyzanowska MK, Zimmermann C, et al. Palliative care and the aggressiveness of end-of-life care in patients with advanced pancreatic cancer. J Natl Cancer Inst. 2015 Jan 20;107(3). pii:dju424. PubMed PMID: 25609233.
   PubMedGoogle Scholar
• Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer. J Clin Oncol 2012 Feb 1;30(4):394–400. PubMed PMID: 22203758.
   PubMed Web of Science ®Google Scholar
• Le DT, Wang-Gillam A, Picozzi V, et al. Safety and survival with gvax pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Feb 12;33:1325–1333. English.
   PubMed Web of Science ®Google Scholar
• Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016 Feb 15;22(4):807–812. PubMed PMID: 26515495.
   PubMed Web of Science ®Google Scholar
• Hwang CI, Boj SF, Clevers H, et al. Pre-clinical models of pancreatic ductal adenocarcinoma. J Pathol. 2015 Sep 30;238:197–204. PubMed PMID: 26419819.
   PubMed Web of Science ®Google Scholar
• Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015 Jan 15;160(1–2):324–338. PubMed PMID: 25557080; Pubmed Central PMCID: 4334572.
   PubMed Web of Science ®Google Scholar
• Capello M, Lee M, Wang H, et al. Carboxylesterase 2 as a determinant of response to irinotecan and neoadjuvant FOLFIRINOX therapy in pancreatic ductal adenocarcinoma. J Natl Cancer Inst. 2015 Aug;107(8). PubMed PMID: 26025324; Pubmed Central PMCID: 4554193.
   PubMedGoogle Scholar
• Orlandi A, Calegari MA, Martini M, et al. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clin Trans Oncol. 2016 Jan 7. PubMed PMID: 26742940. [Epub ahead of print]
   Google Scholar
• Sinn M, Riess H, Sinn BV, et al. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - results from the CONKO-001 trial. Eur J Cancer. 2015;51(12):1546–1554. PubMed PMID: 26049689.
   PubMed Web of Science ®Google Scholar
• Poplin E, Wasan H, Rolfe L, et al. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol 2013 Dec 10;31(35):4453–4461. PubMed PMID: 24220555.
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Plaza C, Musteanu M, et al. SPARC expression did not predict efficacy of nab-paclitaxel plus gemcitabine or gemcitabine alone for metastatic pancreatic cancer in an exploratory analysis of the Phase III mpact trial. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2015 Jul 13;21:4811–4818. PubMed PMID: 26169969.
   PubMed Web of Science ®Google Scholar
• Sinn M, Sinn BV, Striefler JK, et al. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Ann Oncol. 2014;25(5):1025–1032. PubMed PMID: 24562449.
   PubMed Web of Science ®Google Scholar
• Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 May 3;17:500–503. PubMed PMID: 21460848.
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, McMillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744. PubMed PMID: 25855536.
   PubMed Web of Science ®Google Scholar
• Waddell N, Pajic M, Patch A-M, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015 Mar 26;518(7540):495–501. PubMed PMID: 25719666.
   PubMed Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012 Oct 24;491:399–405. PubMed PMID: 23103869.
   PubMed Web of Science ®Google Scholar
• Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016 Feb 24;531:47–52. PubMed PMID: 26909576.
   PubMed Web of Science ®Google Scholar
• Ting DT, Wittner BS, Ligorio M, et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014 Sep 17;8:1905–1918. PubMed PMID: 25242334.
   PubMed Web of Science ®Google Scholar
• Bobek V, Gurlich R, Eliasova P, et al. Circulating tumor cells in pancreatic cancer patients: enrichment and cultivation. World J Gastroenterol. 2014 Dec 7;20(45):17163–17170. PubMed PMID: 25493031.
   PubMed Web of Science ®Google Scholar
• Vietsch EE, Van Eijck CH, Wellstein A. Circulating DNA and micro-RNA in patients with pancreatic cancer. Pancreat Disord Ther. 2015 Jun;5(2). pii:156. PubMed PMID: 26161297; Pubmed Central PMCID: PMC4494744.
   PubMedGoogle Scholar
• Portal A, Pernot S, Tougeron D, et al. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 2015 Sep 29;113(7):989–995. PubMed PMID: 26372701; Pubmed Central PMCID: 4651133.
   PubMed Web of Science ®Google Scholar
• Andor N, Graham TA, Jansen M, et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med. 2016;22(1):105–113. PubMed PMID: 26618723.
   PubMed Web of Science ®Google Scholar
• Schwarz RF, Ng CK, Cooke SL, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015;12(2):e1001789. PubMed PMID: 25710373; Pubmed Central PMCID: 4339382.
   PubMed Web of Science ®Google Scholar